MGX
NASDAQMetagenomi Therapeutics Inc.
News25/Ratings9
News · 26 weeks25-60%
2026-04-192026-10-11
Mix1090d
- Insider4(40%)
- Other3(30%)
- SEC Filings3(30%)
Latest news
25 items- PRMetagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceEMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled "Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0" at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 10:30 a.m. ET, being held in New York, NY. A live webcast of the event will be made available on the "News & Events" page in the Investors section of the Company’s web
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- INSIDERDirector Reid Laurence bought $23,401 worth of shares (20,000 units at $1.17) (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $415 worth of shares (358 units at $1.16), decreasing direct ownership by 0.28% to 126,133 units (SEC Form 4) (withholding tax)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Irish Jian sold $2,479 worth of shares (2,140 units at $1.16), decreasing direct ownership by 0.57% to 375,393 units (SEC Form 4) (withholding obligation)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $2,214 worth of shares (1,911 units at $1.16), decreasing direct ownership by 0.92% to 206,580 units (SEC Form 4) (for withholding tax)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- PRMetagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare ConferenceEMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at 12:45 p.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/eve
- SECSEC Form 10-Q filed by Metagenomi Therapeutics Inc.10-Q - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial ResultsRemains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. "During the sec
- PRProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioEMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies. "We believe long-acting agents with the potential to be dosed on a monthly or quarterly basis represent one of the most important next frontiers for the l
- ANALYSTChardan Capital Markets resumed coverage on Metagenomi Therapeutics with a new price targetChardan Capital Markets resumed coverage of Metagenomi Therapeutics with a rating of Buy and set a new price target of $5.00
- INSIDERSEC Form 4 filed by Director Reid Laurence4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Dere Willard H4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Bjerkholt Eric4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Eckhardt Juergen4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Irish Jian sold $4,854 worth of shares (3,737 units at $1.30), decreasing direct ownership by 0.98% to 377,533 units (SEC Form 4) (for tax liability)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $725 worth of shares (558 units at $1.30), decreasing direct ownership by 0.44% to 126,491 units (SEC Form 4) to satisfy withholding tax4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- PRMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceEMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events. About Metagenomi
- SECSEC Form 10-Q filed by Metagenomi Therapeutics Inc.10-Q - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsOn track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application ("IND") in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative
- SECSEC Form DEFA14A filed by Metagenomi Therapeutics Inc.DEFA14A - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECSEC Form DEF 14A filed by Metagenomi Therapeutics Inc.DEF 14A - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
MGX FAQ
6 questionsWhere does MGX stock trade?
Metagenomi Therapeutics Inc. (MGX) is listed on NASDAQ.What sector and industry is MGX in?
Metagenomi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Metagenomi Therapeutics Inc. go public?
Metagenomi Therapeutics Inc. (MGX) completed its IPO in 2024.What are analysts saying about MGX?
Metagenomi Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy with a $500.00 price target on 2026-07-07. Recent price targets range from $500.00 to $2300.00.What companies are similar to MGX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare MGX side-by-side with any of them on Quantisnow.How can I track MGX on Quantisnow?
Quantisnow aggregates Metagenomi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MGX to receive live email and push alerts on every new disclosure.